July 27, 2020 -- The U.S. Food and Drug Administration (FDA) has cleared LabCorp's COVID-19 reverse transcription polymerase chain reaction (RT-PCR) test for use in screening asymptomatic people.
The agency renewed emergency use authorization (EUA) for LabCorp's assay with two new applications: testing asymptomatic individuals and allowing for pooled testing with up to five individual swab specimens.
"[The] FDA's authorization of the first diagnostic test to be used for anyone, regardless of whether they are showing symptoms of COVID-19 or have other exposure risk factors, is a step toward the type of broad screening that may help enable the reopening of schools and workplaces," said FDA Commissioner Dr. Stephen Hahn in a statement released by the agency.
LabCorp's test is available by prescription only but may be used at home with the company's Pixel home collection kits as well as by a healthcare provider, although pooled samples must be collected by a healthcare provider, the FDA said.
The agency paved the way for tests screening asymptomatic people through guidance issued in June.
When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.Yes, Keep Me Current